Feasibility study of a docosahexaenoic acid optimized nutraceutical formulation on the macular levels of lutein in a healthy Mediterranean population.

INTRODUCTION Macular pigment optical density plays a pivotal role in maintaining macular structure and functioning. Research shows that daily consumption of lutein reduces the risk of eye diseases such as age-related macular degeneration. OBJECTIVE This study analyzes the influence of a supplementation containing lutein and antioxidant vitamins either with or without docosahexaenoic acid (DHA), with the main objective of identifying macular pigment optical density (MPOD) changes in both eyes at the end of the follow-up using the Visucam® retinograph. The secondary endpoint was to determine variation in the lutein and DHA levels in plasma and red blood cell membranes respectively. METHODS One hundred healthy participants (200 eyes) aged 40-70 years (mean age 49.3 years, SEM=13.7) were randomized in a 1:1 ratio to receive daily one of the following supplements for 3 months: Lutein group (LT-G, n=49), Lutein /Docosahexaenoic acid group (LT/DHA-G, n= 51). The MPOD was measured at baseline and end of the follow-up by retinography (Visucam® retinograph). Lutein in plasma was determined by HPLC and DHA in red blood cell membranes was analyzed by gas chromatograph/mass spectrometer. RESULTS From baseline, macular pigment optical density showed significantly higher values in the Lutein/DHA group than in the Lutein group at the end of the study (p<0.0001). Significantly higher Lutein in plasma (p<0.0001) and DHA (p<0.0001) levels in the red blood cell membrane were seen in the Lutein/DHA group than in the Lutein group at the 3-month follow-up. CONCLUSION Lutein supplementation improves macular pigment optical density in healthy subjects from a Mediterranean population being significantly increased in the presence of DHA. Therefore, our findings highlight the relevance of the adjunctive role of DHA for a better Lutein availability.